Cathie Wood and ARK's 5 BILLION DOLLAR Opportunity ( ARKG's Second Largest Holding HUGE NEWS)
ARK Invest has over 870 million in this stock. It is currently their number 2 holding in the ARKG ETF, which is focused on Genomics.
ARKG holdings “In this video I’m going to show you why it is up over 35% this week, and why I think it will continue to be a top performer in the ARKG ETF . If you enjoy the video, make sure you subscribe and click the notification bell so you can see this time sensitive information as quickly as possible.
Genomics- structure, function, evolution and mapping of genomes Pacific Biosciences is a biotech company that develops and manufactures systems for gene sequencing and some novel real time biological observation. They focus on long read sequencing, which im contrast to short read sequencing, breaks a genome into larger pieces than SRS and uses efficient computer algorithms to reassemble the genomes. Long read sequencing is seen as less accurate but more complete, and short read is more accurate but less compete. Think of it like a puzzle, where short read sequencing is breaking the puzzle into a bunch of little pieces and solving it, and long read sequencing as breaking the puzzle down into pieces that are bigger than a SRS, and solving the puzzle. Ark invest and Cathie Wood believe that Long read sequencing is superior due to its ability to provide the most in depth variant detection.Short read sequencing is used more often due to it being more cost effective.
ARK invest believes due to something called Wright’s Law, which states every cumulative doubling in data produced, will result in a cost decline of 28%. This means the more data produced on LRS, the cheaper it will be, which will lead to more companies switching from short read to long read sequencing.Cathie Wood and Ark invest also expects this to lead to an annual growth rate of 82% for Long read sequencing revenues through 2025, from 250 million to 5 billion in total. This benefits PACB as they are the leading LRS company.

PacBio Earnings-
Revenue fell 3% year over year to 27.1 million.
74.9 million in net income .37 EPS Which missed expectations.
Cash- Ended the quarter with cash, cash equivalents, and investments totaling 318.8 million, which is about a 50% increase from Q3 of 208.6 million. Most of this cash came from an offering in November which netted 93.6 million.
PACB was affected by the pandemic, where some of their customers shut down operations.
Placed 35 Sequel II systems in Q4 which brings their total to 203. Sequel II systems provide scientists with access to cost effect and highly accurate long read sequencing. Product revenue fell 4% year over year, but increased 50% from Q3, showing the effects of the pandemic on sales, and the rebound of sales in Q4.SoftBank Investment- Softbank Group is planning on investing 900 million into PacB, at an average cost of 43.5 per share, which results in a 6% stake. which caused shares to jump over 25% on February 10th. This will substantially increase their cash to over 1 billion, giving them the ability to advance long read sequencing technologies. PACB CEO said the investment will enable to company to lower the prices for its system.
This puts PACB in a better financial position in order to excel in the Long read space over the next 5 years, and also shows us why Cathie Wood and ARK are invested into it








cathie wood,cathie woods,ark invest,investing,stocks,kathy wood,cathie wood genomics,personal finance,ark,invest,stock market, ark invest,ark invest cathie wood,cathie wood ark investment,ark invest big ideas 2021,stock investing,stock,ark genomics, arkg,arkg etf,arkg genomics,arkg stock,ark etf,arkk,arkg genomic stocks, Pacb, Pacb stock, pacific biosciences, genomics

свернуть